Coronary artery Ectatic/Aneurysmatic disease: From pathophysiology to management
Progress in Cardiovascular Diseases · 2026
DOI: 10.1016/j.pcad.2026.05.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2026. Verfasst von George Markousis-Mavrogenis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Angiology and Pneumology, Heidelberg University, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site He…. Hauptthemen laut MEDLINE: Coronary Aneurysm, Coronary Vessels, Cardiovascular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Coronary artery ectatic/aneurysmatic disease (CAE/CAA) is a rare but clinically significant condition characterized by abnormal dilatation of the coronary arteries, either diffusely (CAE) or focally (CAA). Its pathophysiology is multifactorial, involving atherosclerosis, genetic predisposition, systemic autoimmunity, and infectious triggers, with distinct etiologies in adults (e.g., atherosclerosis, connective tissue disorders) and children (e.g., Kawasaki disease, multisystem inflammatory syndrome in children). CAE/CAA is associated with increased risks of thrombosis, embolization, and acute coronary syndromes, even in the absence of obstructive coronary artery disease. Diagnostic evaluation relies on multimodality imaging, including transthoracic echocardiography (especially in children), computed tomography coronary angiography, cardiovascular magnetic resonance angiography, and invasive coronary angiography with intravascular ultrasound. Each modality offers unique advantages, but challenges such as radiation exposure, contrast use, expertise and availability persist. Therapeutic management remains empirical due to a lack of randomized trials. In adults, risk factor modification, statins, angiotensin converting enzyme inhibitors / angiotensin receptor blockers, calcium channel blockers are commonly used. Optimal strategies for antiplatelet/anticoagulant treatment are currently under debate. In children, anticoagulation and antiplatelet therapy are recommended for large aneurysms, particularly in Kawasaki disease. Future research should focus on elucidating pathophysiology, comparing imaging modalities, and establishing evidence-based treatment strategies to improve outcomes in this complex patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Angiology and Pneumology, Heidelberg University, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, Germany; University Research Institute of Maternal…
- John's Hopkins University Hospital, Baltimore, USA.
- University of Texas, TX, USA.
- University of Lausanne, Lausanne, Switzerland.
- University Research Institute of Maternal and Child Health and Precision Medicine and UNESCO Chair in Adolescent Health Care, Medical School, National and Kapodistrian University of Athens, Aghia Sophia Children's Hospi…
Zitieren
APA
Markousis-Mavrogenis, G., Ebrahimihoor, E., Lima, J. A. C., Weber, B., Schwitter, J., & Mavrogeni, S. I. (2026). Coronary artery Ectatic/Aneurysmatic disease: From pathophysiology to management. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2026.05.003
Vancouver
Markousis-Mavrogenis G, Ebrahimihoor E, Lima JAC, Weber B, Schwitter J, Mavrogeni SI. Coronary artery Ectatic/Aneurysmatic disease: From pathophysiology to management. Progress in Cardiovascular Diseases. 2026. doi:10.1016/j.pcad.2026.05.003
BibTeX
@article{MarkousisMavrogenis2026,
author = {Markousis-Mavrogenis, George and Ebrahimihoor, Elnaz and Lima, Joao A C and Weber, Brittany and Schwitter, Juerg and Mavrogeni, Sophie I},
title = {Coronary artery Ectatic/Aneurysmatic disease: From pathophysiology to management},
journal = {Progress in Cardiovascular Diseases},
year = {2026},
doi = {10.1016/j.pcad.2026.05.003}
}
EUVIMED